Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13260289 | 0.80 | HSD11B1 (0.42) | L3MBTL1HSD11B1EPHX2EPHX1 | |
| SCHEMBL1016262 | 0.79 | L3MBTL1 (0.65) | L3MBTL1HSD11B1EPHX2EPHX1HSD17B10 | |
| SCHEMBL12070487 | 0.77 | HSD11B1 (0.65) | L3MBTL1HSD11B1EPHX2EPHX1HSD17B10 | |
| SCHEMBL13702321 | 0.77 | L3MBTL1 (0.72) | L3MBTL1HSD11B1EPHX2HSD17B10ALDH1A1 | |
| SCHEMBL13701832 | 0.77 | EPHX2 (0.61) | L3MBTL1HSD11B1EPHX2EPHX1HSD17B10 | |
| SCHEMBL12968364 | 0.77 | L3MBTL1 (0.72) | L3MBTL1HSD11B1EPHX2HSD17B10ALDH1A1 | |
| SCHEMBL1402737 | 0.76 | L3MBTL1 (0.66) | L3MBTL1HSD11B1EPHX2HSD17B10ALDH1A1 | |
| SCHEMBL13760993 | 0.76 | HSD11B1 (0.38) | L3MBTL1HSD11B1EPHX2EPHX1HSD17B10 | |
| SCHEMBL15224285 | 0.76 | L3MBTL1 (0.59) | L3MBTL1HSD11B1EPHX2HSD17B10ALDH1A1 | |
| SCHEMBL1402900 | 0.75 | L3MBTL1 (0.59) | L3MBTL1HSD11B1EPHX2EPHX1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344016-B2 | Pyrazole derivatives as 11-beta-HSD1 inhibitors | ASTRAZENECA AB (SE) | 2013-01-01 | — | — | US | disclosed |
| US-8344016-B2 | Pyrazole derivatives as 11-beta-HSD1 inhibitors | ASTRAZENECA AB (SE) | 2013-01-01 | — | — | US | disclosed |
| US-8344016-B2 | Pyrazole derivatives as 11-beta-HSD1 inhibitors | ASTRAZENECA AB (SE) | 2013-01-01 | — | — | US | disclosed |
| CN-101668524-B | Pyrazole derivatives as 11-beta-HSD 1 inhibitors | ASTRAZENECA AB | 2012-10-24 | — | — | CN | disclosed |
| CN-102503891-A | Pyrazole derivatives as 11-beta-hsd1 inhibitors | ASTRAZENECA AB | 2012-06-20 | — | — | CN | disclosed |
| US-20120041211-A1 | NOVEL PROCESS FOR PREPARING CARBOXY-CONTAINING PYRAZOLEAMIDO COMPOUNDS 597 | ASTRAZENECA INDIA PRIVATE LIMITED (IN) | 2012-02-16 | — | — | US | disclosed |
| US-20120041211-A1 | NOVEL PROCESS FOR PREPARING CARBOXY-CONTAINING PYRAZOLEAMIDO COMPOUNDS 597 | ASTRAZENECA INDIA PRIVATE LIMITED (IN) | 2012-02-16 | — | — | US | disclosed |
| US-20120041211-A1 | NOVEL PROCESS FOR PREPARING CARBOXY-CONTAINING PYRAZOLEAMIDO COMPOUNDS 597 | ASTRAZENECA INDIA PRIVATE LIMITED (IN) | 2012-02-16 | — | — | US | disclosed |
| CN-102300851-A | Novel process for preparing carboxy-containing pyrazoleamido compounds 597 | — | 2011-12-28 | — | — | CN | disclosed |
| EP-2391607-A1 | NOVEL PROCESS FOR PREPARING CARBOXY-CONTAINING PYRAZOLEAMIDO COMPOUNDS 597 | AstraZeneca AB (SE) | 2011-12-07 | — | — | EP | disclosed |
| US-20090221660-A1 | NOVEL CRYSTALLINE FORMS OF 4-[4-(2-ADAMANTYLCARBAMOYL)-5-TERT-BUTYL-PYRAZOL-1-YL]BENZOIC ACID 471 | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090221660-A1 | NOVEL CRYSTALLINE FORMS OF 4-[4-(2-ADAMANTYLCARBAMOYL)-5-TERT-BUTYL-PYRAZOL-1-YL]BENZOIC ACID 471 | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090221660-A1 | NOVEL CRYSTALLINE FORMS OF 4-[4-(2-ADAMANTYLCARBAMOYL)-5-TERT-BUTYL-PYRAZOL-1-YL]BENZOIC ACID 471 | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090221663-A1 | PYRAZOLE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| WO-2009098501-A1 | NOVEL CRYSTALLINE FORMS OF 4- [4- (2-ADAMANTYLCARBAM0YL) -5-TERT-BUTYL-PYRAZOL-1-YL] BENZOIC ACID | ASTRAZENECA AB (SE) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009098501-A1 | NOVEL CRYSTALLINE FORMS OF 4- [4- (2-ADAMANTYLCARBAM0YL) -5-TERT-BUTYL-PYRAZOL-1-YL] BENZOIC ACID | ASTRAZENECA AB (SE) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009060232-A1 | 4-[4-(2-ADAMANTYLCARBAMOYL)-5-TERT-BUTYL-PYRAZOL-1-YL]BENZOIC ACID - 465 | ASTRAZENECA AB (SE) | 2009-05-14 | — | — | WO | disclosed |
| WO-2009060232-A1 | 4-[4-(2-ADAMANTYLCARBAMOYL)-5-TERT-BUTYL-PYRAZOL-1-YL]BENZOIC ACID - 465 | ASTRAZENECA AB (SE) | 2009-05-14 | — | — | WO | disclosed |
| WO-2008099145-A1 | PYRAZOLE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008099145-A1 | PYRAZOLE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221660-A1 | NOVEL CRYSTALLINE FORMS OF 4-[4-(2-ADAMANTYLCARBAMOYL)-5-TERT-BUTYL-PYRAZOL-1-YL]BENZOIC ACID 471 | HSD11B1, SRD5A1, CYP4A11 | L3MBTL1 4739/4885HSD11B1 1/4885EPHX2 1495/4885 |
| US-20120041211-A1 | NOVEL PROCESS FOR PREPARING CARBOXY-CONTAINING PYRAZOLEAMIDO COMPOUNDS 597 | CYP3A7, CYP2C9, CYP2A7 | L3MBTL1 4024/4885HSD11B1 3393/4885EPHX2 460/4885 |
| US-20090221663-A1 | PYRAZOLE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | HSD11B1, HSD3B1, HSD11B2 | L3MBTL1 4595/4885HSD11B1 1/4885EPHX2 1955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.